Health Canada

Sunshine Biopharma's subsidiary Nora Pharma received Health Canada approval to commercialize domperidone, a prescription medication for chemotherapy-induced nausea and vomiting.

Health Canada granted Notice of Compliance for Yesintek, Biocon Biologics' ustekinumab biosimilar to Stelara, on October 17, 2025, enabling commercial launch in mid-October.

Sona Nanotech's targeted hyperthermia therapy demonstrated an 80% response rate in a first-in-human study of 10 patients with immunotherapy-resistant cutaneous metastatic melanoma.

Ontario introduces the Funding Accelerated for Specific Treatments (FAST) program, the first initiative of its kind in Canada to fast-track access to breakthrough cancer drugs.

Health Canada has approved AGAMREE (vamorolone) as the first treatment for Duchenne muscular dystrophy in patients aged 4 years and older, marking a historic milestone for Canadian DMD care.

Merit Medical Systems has enrolled the first patient in its WRAP North America registry, a prospective multicenter study designed to collect real-world safety and effectiveness data on the WRAPSODY Cell-Impermeable Endoprosthesis for hemodialysis patients.

Health Canada granted conditional marketing authorization for AMTAGVI, marking the first T-cell therapy approved for solid tumors in Canada, specifically for advanced melanoma treatment.

Health Canada approved Ozempic on August 13 to reduce kidney deterioration risk in Type 2 diabetes patients with chronic kidney disease.

Amansa Investments has completed a ₹250 crore pre-IPO investment in pharmaceutical formulations company Rubicon Research, acquiring shares at ₹484.47 per share.

Iovance Biotherapeutics reduced its workforce by 19% in Q3 2025 and targets $100 million in annual savings to extend cash runway to late 2026.